Trial Profile
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary) ; Etanercept
- Indications Palmoplantar pustulosis; Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms UNCOVER-3
- Sponsors Eli Lilly and Company
- 21 Mar 2023 Results of post-hoc pooled analysis assessing NPF treatment targets in the overall population, and biologic-experienced and -naive subpopulations across IXORA-R, IXORA-S, integrated UNCOVER-2-3 presented at the American Academy of Dermatology annual Meeting 2023
- 21 Mar 2023 Results of post-hoc pooled analysis assessing patient-reported fatigue, using the SF-36 vitality domain, in patients who received ixekizumab 80 mg Q2W for 12 weeks for moderate-to-severe psoriasis across UNCOVER-1 (N=433), UNCOVER-2 (N=351), UNCOVER-3 (N=385), and IXORA-S (N=136) SPIRIT-H2H presented at the American Academy of Dermatology annual Meeting 2023
- 21 Mar 2023 Results of post-hoc pooled analysis assessing the disease improvement and clearance of palmoplantar PsO in the palms and soles of patients with moderate-to-severe plaque PsO and baseline palmoplantar PsO who were treated with ixekizumab for up to 5 years across 6 clinical trials (NCT01474512, NCT01597245, NCT01646177, NCT03364309, NCT02561806 and NCT03073200), presented at the American Academy of Dermatology annual Meeting 2023.